149 related articles for article (PubMed ID: 8927669)
1. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(1):175-80. PubMed ID: 8927669
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment of body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
Phillips KA; Albertini RS; Siniscalchi JM; Khan A; Robinson M
J Clin Psychiatry; 2001 Sep; 62(9):721-7. PubMed ID: 11681769
[TBL] [Abstract][Full Text] [Related]
4. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
Joffe RT; Schuller DR
J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
[TBL] [Abstract][Full Text] [Related]
5. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach.
Phillips KA; Hollander E
Body Image; 2008 Mar; 5(1):13-27. PubMed ID: 18325859
[TBL] [Abstract][Full Text] [Related]
6. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
8. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
[TBL] [Abstract][Full Text] [Related]
9. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
Fischer P; Tauscher J; Küfferle B; Kasper S
Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Landén M; Björling G; Agren H; Fahlén T
J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
[TBL] [Abstract][Full Text] [Related]
12. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
Bouwer C; Stein DJ
S Afr Med J; 1997 Apr; 87(4 Suppl):534-7, 540. PubMed ID: 9180827
[TBL] [Abstract][Full Text] [Related]
13. Buspirone augmentation of antidepressant therapy.
Dimitriou EC; Dimitriou CE
J Clin Psychopharmacol; 1998 Dec; 18(6):465-9. PubMed ID: 9864079
[TBL] [Abstract][Full Text] [Related]
14. An open-label study of escitalopram in body dysmorphic disorder.
Phillips KA
Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
[TBL] [Abstract][Full Text] [Related]
15. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia.
Van Ameringen M; Mancini C; Wilson C
J Affect Disord; 1996 Jul; 39(2):115-21. PubMed ID: 8827420
[TBL] [Abstract][Full Text] [Related]
16. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
17. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Landén M; Eriksson E; Agren H; Fahlén T
J Clin Psychopharmacol; 1999 Jun; 19(3):268-71. PubMed ID: 10350034
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Phillips KA; Albertini RS; Rasmussen SA
Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
Phillips KA
Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
[TBL] [Abstract][Full Text] [Related]
20. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
